Published in J Nucl Med on August 18, 2010
Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg (2017) 1.36
Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol (2011) 1.22
Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res (2013) 1.14
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging (2011) 1.13
Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS One (2013) 1.12
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? Eur J Nucl Med Mol Imaging (2011) 1.09
The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging (2014) 1.01
Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy. EJNMMI Res (2012) 1.01
Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging (2013) 0.99
Current and future treatments for hepatocellular carcinoma. World J Gastroenterol (2015) 0.92
Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol (2014) 0.91
Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post-Radioembolization (90)Y PET. Front Oncol (2014) 0.91
Positron emission tomography image-guided drug delivery: current status and future perspectives. Mol Pharm (2014) 0.88
Optimal design of anger camera for bremsstrahlung imaging: monte carlo evaluation. Front Oncol (2014) 0.86
Hepatic radioembolization as a bridge to liver surgery. Front Oncol (2014) 0.85
Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging (2015) 0.85
Newer treatments for advanced hepatocellular carcinoma. Korean J Intern Med (2014) 0.85
Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging (2015) 0.83
Theranostic Imaging of Yttrium-90. Biomed Res Int (2015) 0.83
Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation. Hepatobiliary Surg Nutr (2017) 0.81
High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization. Liver Int (2016) 0.80
Dosimetry for radiopharmaceutical therapy. Semin Nucl Med (2014) 0.79
Plasmalemmal Vesicle Associated Protein (PLVAP) as a therapeutic target for treatment of hepatocellular carcinoma. BMC Cancer (2014) 0.78
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART) combined with external beam radiation therapy. Eur J Nucl Med Mol Imaging (2012) 0.78
Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol (2014) 0.78
Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours. Eur J Nucl Med Mol Imaging (2013) 0.78
The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). Eur J Nucl Med Mol Imaging (2014) 0.78
Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol (2015) 0.77
Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models. Int J Radiat Oncol Biol Phys (2016) 0.76
Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients. EJNMMI Res (2017) 0.75
Practical reconstruction protocol for quantitative (90)Y bremsstrahlung SPECT/CT. Med Phys (2016) 0.75
Dose evaluation for skin and organ in hepatocellular carcinoma during angiographic procedure. J Exp Clin Cancer Res (2013) 0.75
Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Phys (2015) 0.75
Computational simulation of the predicted dosimetric impact of adjuvant yttrium-90 PET/CT-guided percutaneous ablation following radioembolization. EJNMMI Res (2016) 0.75
Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary Surg Nutr (2017) 0.75
A review of 3D image-based dosimetry, technical considerations and emerging perspectives in (90)Y microsphere therapy. J Diagn Imaging Ther (2015) 0.75
Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma (2014) 0.75
Hybrid Imaging for Patient-Specific Dosimetry in Radionuclide Therapy. Diagnostics (Basel) (2015) 0.75
Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools. Biomedicines (2016) 0.75
From fixed activities to personalized treatments in radionuclide therapy: lost in translation? Eur J Nucl Med Mol Imaging (2017) 0.75
Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. Eur J Nucl Med Mol Imaging (2017) 0.75
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology (2011) 3.26
Twenty years of radiobiology in clinical practice: the Italian contribution. Tumori (2015) 1.98
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol (2013) 1.95
Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med (2002) 1.73
Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.68
Zero ischemia laparoscopic partial nephrectomy after superselective transarterial tumor embolization for tumors with moderate nephrometry score: long-term results of a single-center experience. J Endourol (2011) 1.57
A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys (2005) 1.49
Phase I-II study of intraoperative radiation therapy (IORT) after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.46
Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys (2013) 1.45
Feasibility and limits of split liver transplantation from pediatric donors: an italian multicenter experience. Ann Surg (2006) 1.43
Donor safety in living related liver transplantation: underestimation of the risks for deep vein thrombosis and pulmonary embolism. Liver Transpl (2002) 1.27
Testis metastasis as an initial manifestation of an occult gastrointestinal cancer. Anticancer Res (2004) 1.09
In regard to Vogelius and Bentzen. Int J Radiat Oncol Biol Phys (2013) 1.05
Modified liver hanging maneuver during orthotopic liver transplantation with inferior vena cava preservation. Transplantation (2003) 1.04
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology (2009) 1.02
Detection of a suspected bronchobiliary fistula by hepatobiliary scintigraphy. Ann Nucl Med (2008) 1.01
The ALPPS procedure: a surgical option for hepatocellular carcinoma with major vascular invasion. World J Surg (2014) 1.01
153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging (2004) 1.00
Solitary fibrous tumor of the liver. J Hepatobiliary Pancreat Surg (2005) 0.99
Laparoscopic and robotic partial nephrectomy without renal ischaemia for tumours larger than 4 cm: perioperative and functional outcomes. World J Urol (2012) 0.99
Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J Exp Clin Cancer Res (2013) 0.99
Setup verification and in vivo dosimetry during intraoperative radiation therapy (IORT) for prostate cancer. Med Phys (2007) 0.97
Perioperative outcomes of laparoscopic and robot-assisted major hepatectomies: an Italian multi-institutional comparative study. Surg Endosc (2014) 0.96
Prevalence, mass, and glucose-uptake activity of ¹⁸F-FDG-detected brown adipose tissue in humans living in a temperate zone of Italy. PLoS One (2013) 0.96
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer (2005) 0.94
Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res (2009) 0.94
IsoBED: a tool for automatic calculation of biologically equivalent fractionation schedules in radiotherapy using IMRT with a simultaneous integrated boost (SIB) technique. J Exp Clin Cancer Res (2011) 0.93
In vivo dosimetry with MOSFETs: dosimetric characterization and first clinical results in intraoperative radiotherapy. Int J Radiat Oncol Biol Phys (2005) 0.92
Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer. Int J Radiat Oncol Biol Phys (2007) 0.90
Long-term central venous catheterization via persistent left superior vena cava: a case report. Support Care Cancer (2003) 0.88
A study of the effect of setup errors and organ motion on prostate cancer treatment with IMRT. Int J Radiat Oncol Biol Phys (2006) 0.87
Abscopal effect of radiation therapy: Interplay between radiation dose and p53 status. Int J Radiat Biol (2014) 0.87
Malignant haemangiopericytoma of the mesorectum. Chir Ital (2005) 0.87
Accelerated hypofractionated radiotherapy as adjuvant regimen after conserving surgery for early breast cancer: interim report of toxicity after a minimum follow up of 3 years. J Exp Clin Cancer Res (2010) 0.87
Liver hanging maneuver: an anatomic and clinical review. Am J Surg (2007) 0.86
A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2010) 0.86
Total abdominal approach for postero-superior segments (7, 8) in laparoscopic liver surgery: a multicentric experience. Updates Surg (2015) 0.86
Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. Anticancer Res (2003) 0.85
Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of articledeveloping erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. BMC Cancer (2011) 0.84
Analysis of salivary flow and dose-volume modeling of complication incidence in patients with head-and-neck cancer receiving intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2009) 0.84
Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. Int J Radiat Oncol Biol Phys (2008) 0.84
High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Thyroid (2014) 0.84
Laparoscopic Simultaneous Resection of Colorectal Primary Tumor and Liver Metastases: Results of a Multicenter International Study. World J Surg (2015) 0.83
Isolated pancreatic metastasis of extremity myxoid liposarcoma: Report of a case. Jpn J Clin Oncol (2006) 0.83
Brief report: transient mutism following posterior fossa surgery studied by single photon emission computed tomography (SPECT). Med Pediatr Oncol (2002) 0.83
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol (2007) 0.82
Locally advanced carcinoma of the cecum presenting as a right inguinal hernia: a case report and review of the literature. J Med Case Rep (2013) 0.82
Influence of intensity-modulated radiation therapy technique on xerostomia and related quality of life in patients treated with intensity-modulated radiation therapy for nasopharyngeal cancer. Head Neck (2011) 0.82
Implementation of a new cost efficacy method for blood irradiation using a non dedicated device. J Exp Clin Cancer Res (2011) 0.82
Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors. Theor Biol Med Model (2012) 0.82
Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. Radiat Oncol (2012) 0.82
A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment. Phys Med Biol (2008) 0.81
Liver transplantation for recurrent hepatic adenoma. World J Hepatol (2013) 0.81
Radiation protection measurements around a 12 MeV mobile dedicated IORT accelerator. Med Phys (2010) 0.81
Cystic echinococcosis in a single tertiary care center in Rome, Italy. Biomed Res Int (2013) 0.81
Short-term follow-up of radioembolization with yttrium-90 microspheres before liver transplantation: new perspectives in advanced hepatocellular carcinoma. Transplantation (2010) 0.80
Patient positioning in the proton radiotherapy era. J Exp Clin Cancer Res (2010) 0.80
Intraoperative radiation therapy as an "early boost" in locally advanced head and neck cancer: preliminary results of a feasibility study. Head Neck (2008) 0.80
Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control. J Exp Clin Cancer Res (2013) 0.79
HF ultrasound vs PET-CT and telethermography in the diagnosis of In-transit metastases from melanoma: a prospective study and review of the literature. J Exp Clin Cancer Res (2014) 0.79
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis. Hepatol Res (2013) 0.79
Monte Carlo dose voxel kernel calculations of beta-emitting and Auger-emitting radionuclides for internal dosimetry: A comparison between EGSnrcMP and EGS4. Med Phys (2006) 0.79
Histological basis of the liver hanging maneuver. Surg Radiol Anat (2008) 0.79
Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres. J Exp Clin Cancer Res (2013) 0.78
FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases. J Exp Clin Cancer Res (2011) 0.78
Performing the ALPPS Procedure by Anterior Approach and Liver Hanging Maneuver. Ann Surg (2016) 0.78
A new model for predicting acute mucosal toxicity in head-and-neck cancer patients undergoing radiotherapy with altered schedules. Int J Radiat Oncol Biol Phys (2012) 0.78
Toxicity and cosmesis outcomes after single fraction partial breast irradiation in early stage breast cancer. Radiat Oncol (2011) 0.78
Potential third-party radiation exposure from patients undergoing therapy with 131I for thyroid cancer or metastases. Health Phys (2015) 0.78
Tissue heterogeneity in IMRT dose calculation for lung cancer. Med Dosim (2010) 0.78
Superselective embolization as first step of laparoscopic partial nephrectomy. Urology (2007) 0.78
In regard to Miralbell et al. Re: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta=1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys (2013) 0.78
Monitoring of people and workers exposure to the electric, magnetic and electromagnetic fields in an Italian National Cancer Institute. J Exp Clin Cancer Res (2008) 0.77
Biological optimization of heterogeneous dose distributions in systemic radiotherapy. Med Phys (2006) 0.77